Companies › AVVA Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Clotrimazole Cytochrome P450 51 inhibitor | ERGOSTEROL | Phase 2 | Candidal Vulvovaginitis (ICD-10 Code: B37.3) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06835361 | Clotrimazole | Phase 2 | Candidal Vulvovaginitis (ICD-10 Code: B37.3) | Infectious disease | Sep 2025 |
–
Vasomune Therapeutics Altesa Biosciences Eagle Pharmaceuticals Code Pharma Peptilogics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.